J&J again faces off-label marketing claims in Risperdal case of boy who grew breasts

Johnson & Johnson ($JNJ) some time back agreed to pay $2.2 billion to settle federal claims that it improperly marketed the antipsychotic drug Risperdal. But the drugmaker’s legal hassles over the drug are not all done. Last week opening arguments were made in a case in which the drugmaker is accused of marketing the drug for use in young boys and then not sufficiently warning patients that the side effects for some included the possibility they would grow breasts.

Read More.